Emmanuel S. Antonarakis, MD

Emmanuel S. Antonarakis, MD

Johns Hopkins Medical Institutions

Baltimore, Maryland

Dr. Antonarakis is a Professor of Oncology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, as well as the Director of Prostate Cancer Medical Oncology Research and the Co-Director of the Prostate Cancer Multi-Disciplinary Clinic there. He graduated from the University of Wales College of Medicine (United Kingdom) in 2003, and then completed a Residency in Internal Medicine at the Johns Hopkins Bayview Medical Center, followed by a Fellowship in Medical Oncology at the Johns Hopkins Hospital. Since 2010, he has been on the Johns Hopkins faculty as an attending physician and translational researcher in the Department of Oncology. Dr Antonarakis’ clinical interest is the management of prostate cancer and other genitourinary malignancies. His research focuses on drug development and clinical trial design for patients with prostate cancer, as well as cancer genomics. More specifically, he is interested in developing novel androgen-directed therapies, genetically-targeted therapies, and immunotherapies for men with recurrent or advanced prostate cancer, and using germline and cancer genomics to inform precision oncology approaches. He also has an interest in liquid biomarker development, specifically the clinical validation of the AR-V7 marker as well as DNA repair markers and their therapeutic implications. He is currently the PI of several phase II and III prostate cancer trials, and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC) and the Eastern Cooperative Oncology Group (ECOG-ACRIN), as well as the NCI Prostate Cancer Task Force and the NCCN Prostate Cancer Panel. He serves on the editorial boards of several oncology journals, including the Journal of Clinical Oncology. He is the author of >290 peer-reviewed articles and several book chapters, and has edited a textbook about AR signaling in cancer.

Disclosures:

• Consultant/Advisor for: Janssen, Astellas, Sanofi, Dendreon, Bayer, BMS, Amgen, ESSA, Constellation, Blue Earth, Exact Sciences, Invitae, Curium, Pfizer, Merck, AstraZeneca, Clovis, Eli Lilly.

• Grant/Research support from: Janssen, J&J, Sanofi, BMS, Pfizer, AstraZeneca, Novartis, Curium, Constellation, ESSA, Celgene, Merck, Bayer, Clovis.

• Inventions/Patents: Co-inventor of an AR-V7 technology licensed to Qiagen.

Articles by Emmanuel S. Antonarakis, MD

Castration Resistant Prostate Cancer – Developments and Challenges from 2020

In this Platinum Lecture, Emmanuel S. Antonarakis, MD, Professor of Oncology and Urology as well as Director of Prostate Cancer Medical Oncology Research and the Co-Director of the Prostate Cancer Multidisciplinary Clinic at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, summarizes developments from 2020 in mutation-targeted treatments for metastatic castration-resistant prostate cancer (mCRPC). He considers the successes of PARP inhibitors, especially for patients with the BRCA2 mutation, and the limitations of PD1 inhibitors. Dr. Antonarakis concludes by looking at promising research into B7-H3 and PSMA.

Read More

Join the GRU Community

- Why Join? -